SUPPLEMENTARY FIGURE


Supplementary figure 1: risk of relapse depending on the complex version of the score (development cohort)

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

RMD Open

SUPPLEMENTARY TABLES

Supplementary table 1: Area under the ROC curve to predict relapse in the validation cohort across follow-up from AAV diagnosis

Time of follow-up	ROC AUC (95% CI) of the complex score	ROC AUC (95% CI) of the FRS	P value
24 months	0.56 (0.50-0.62)	0.58 (0.52-0.64)	0.0580
36 months	0.60 (0.54-0.65)	0.61 (0.55-0.65)	0.2181
48 months	0.59 (0.53-0.64)	0.59 (0.54-0.65)	0.3916
60 months	0.61 (0.55-0.67)	0.61 (0.56-0.66)	0.9291
72 months	0.66 (0.60-0.72)	0.65 (0.59-0.70)	0.2482
84 months	0.68 (0.62-0.74)	0.67 (0.61-0.72)	0.1938

95 CI: 95% confidence interval
FRS: French Vasculitis Study Group Relapse Score

2